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A B S T R A C T
Background
Many malaria vaccines are currently in development, although very few have been evaluated
for efficacy in the field. Plasmodium falciparum multiple epitope (ME)– thrombospondin-related
adhesion protein (TRAP) candidate vaccines are designed to potently induce effector T cells
and so are a departure from earlier malaria vaccines evaluated in the field in terms of their
mechanism of action. ME-TRAP vaccines encode a polyepitope string and the TRAP sporozoite
antigen. Two vaccine vectors encoding ME-TRAP, plasmid DNA and modified vaccinia virus
Ankara (MVA), when used sequentially in a prime-boost immunisation regime, induce high
frequencies of effector T cells and partial protection, manifest as delay in time to parasitaemia,
in a clinical challenge model.
Methods and Findings
A total of 372 Gambian men aged 15–45 y were randomised to receive either DNA ME-TRAP
followed by MVA ME-TRAP or rabies vaccine (control). Of these men, 296 received three doses
of vaccine timed to coincide with the beginning of the transmission season (141 in the DNA/
MVA group and 155 in the rabies group) and were followed up. Volunteers were given
sulphadoxine/pyrimethamine 2 wk before the final vaccination. Blood smears were collected
weekly for 11 wk and whenever a volunteer developed symptoms compatible with malaria
during the transmission season. The primary endpoint was time to first infection with asexual P.
falciparum. Analysis was per protocol.
DNA ME-TRAP and MVA ME-TRAP were safe and well-tolerated. Effector T cell responses to a
non-vaccine strain of TRAP were 50-fold higher postvaccination in the malaria vaccine group
than in the rabies vaccine group. Vaccine efficacy, adjusted for confounding factors, was 10.3%
(95% confidence interval, 22% to þ34%; p = 0.49). Incidence of malaria infection decreased
with increasing age and was associated with ethnicity.
Conclusions
DNA/MVA heterologous prime-boost vaccination is safe and highly immunogenic for effector
T cell induction in a malaria-endemic area. But despite having produced a substantial reduction
in liver-stage parasites in challenge studies of non-immune volunteers, this first generation T
cell–inducing vaccine was ineffective at reducing the natural infection rate in semi-immune
African adults.
Introduction
The disease burden of malaria has increased in recent years partly because of the rise of drug-
resistant Plasmodium falciparum parasites [1] and insecticide-resistant Anopheline spp. vectors [2].
There is an urgent need for effective malaria control methods to reduce mortality and
morbidity from malaria in endemic countries. Detailed analysis of immunological mechanisms
of immunity against malaria in humans and experimental animals has indicated a likely
protective role for T cell responses against the liver stages of P. falciparum [3,4,5,6,7,8,9].
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Comparison of a variety of means of immunisation to induce
protective T cell responses in animal models has identiﬁed
heterologous prime-boost immunisation, i.e., sequential
immunisation with two different vaccines with the same
recombinant DNA sequence, as a particularly effective
approach [10,11]. DNA and viral vaccines recombinant for a
malarial DNA sequence known as multiple epitope (ME)–
thrombospondin-related adhesion protein (TRAP), which
were designed to induce protective immunogenicity against
liver-stage P. falciparum malaria, were manufactured to
explore this approach [12]. c-interferon T cell responses to
ME and TRAP peptides were associated with protection from
severe malarial anaemia in a prospective study of Kenyan
children [13].
DNA and modiﬁed vaccinia virus Ankara (MVA)’s excellent
safety proﬁles in malaria-naı¨ve and semi-immune volunteers
have been discussed previously [12]. In several studies, prime-
boost immunisation (usually with DNA/MVA) has been highly
immunogenic for CD4þ and CD8þ T cell induction against
infectious pathogens and cancers in both murine and
nonhuman primate studies [14,15,16,17,18,19]. DNA/MVA
vaccination was protective 7 mo after vaccination in an
HIV macaque model [20].
Priming with three 2-mg intramuscular DNA ME-TRAP
vaccinations at 3-wk intervals, followed by boosting with one
intradermal MVA ME-TRAP vaccination of 1.53 108 plaque-
forming units, produced very strong vaccine-induced CD4þ
and CD8þ T cell responses in previous phase I studies in the
United Kingdom [21]. The immunogenicity of two DNA ME-
TRAP primes followed by one MVA ME-TRAP boost at these
doses is similarly high in both the United Kingdom (S.
Dunachie and A. V. S. Hill, unpublished data) and Gambia
[22]. DNA ME-TRAP/MVA ME-TRAP regimens led to a delay
in time to parasitaemia compared to unvaccinated controls
after high-dose heterologous sporozoite challenge of malaria-
naı¨ve individuals [21].
To follow up these encouraging ﬁndings in volunteers, we
have conducted a randomised, controlled trial of DNA ME-
TRAP/MVA ME-TRAP in a rural part of Gambia to explore
whether this vaccine combination could provide protection
against natural P. falciparum infection. We chose a two-DNA
prime, one-MVA boost regimen with 3-wk between doses
because this is a three-dose regimen that would be amenable
to integration with the World Health Organization/United
Nations Children’s Fund Expanded Program on Immuniza-
tion, with the necessary supporting safety and immunoge-
nicity data both from adults in the United Kingdom and
Gambia. We used 3-wk intervals because 4-wk intervals had
not been evaluated in phase I trials previously, hence bridging
studies would be necessary to bridge to the three-dose, 4-wk
interval Expanded Program on Immunization schedule.
Methods
Vaccines
The malarial DNA sequence is known as ME-TRAP. The ME
string contains 14 CD8þ T cell epitopes, one CD4þ T cell
epitope, and two B cell epitopes from six pre-erythrocytic P.
falciparum antigens. It also contains two non-malarial CD4þT
cell epitopes [23]. The ME string is fused in frame to the
entire T9/96 strain of P. falciparum TRAP [10,24,25]. The
individual epitopes making up the ME string are described in
detail elsewhere [23]. The strain of P. falciparum used to
produce the vaccine construct is T9/96. The candidate
malaria vaccines were manufactured to Good Manufacturing
Practice by contract manufacturers (DNA ME-TRAP by
Qiagen, Hilden, Germany; MVA ME-TRAP by IDT, Rosslau,
Germany). DNA ME-TRAP was supplied as a single dose of
2 mg in 2-ml vials. MVA ME-TRAP was supplied as two-dose
vials, each containing 33 108 plaque-forming units in 0.8 ml.
The rabies vaccine (Chiron Behring, Marburg, Germany) was
supplied as a lyophilised single-dose vial with accompanying
diluent and syringe. This vaccine was chosen because of its
public health beneﬁt in Gambia.
Study Setting and Volunteers
Approval was obtained from the Joint Gambian Govern-
ment/Medical Research Council Ethics Committee, the
Oxford Tropical Research Ethics Committee, and the London
School of Hygiene and Tropical Medicine Ethics Committee.
An independent Data and Safety Monitoring Board provided
oversight for the trial. In addition, independent clinical trial
monitors monitored the trial for adherence to International
Committee on Harmonisation Good Clinical Practice guide-
lines.
Malaria incidence is highly seasonal in Gambia. The climate
is typical of sub-Sahelian Africa, with a long dry season
followed by a relatively short rainy season from July to
October. Rainfall averages about 600 mm per year. Morbidity
and mortality from malaria both occur more frequently
during the rainy season. However, in 2002, Gambia experi-
enced a drought, and the malaria season was delayed, with few
disease episodes before October. The entomological inocu-
lation rate varies between less than 1 and greater than 100 in
Gambia [26]. Based on previous years’ data, we assumed that
the average cumulative incidence over a number of years
would be about 60% (interquartile range [IQR], 50%–70%),
with very few years with incidence less than 40% or more
than 90%. Allowing for 15% loss to follow-up, and using a
signiﬁcance level of 0.05, the median power of a study with
372 participants would be 90% (95% conﬁdence interval [CI],
69%–98%) if the vaccine efﬁcacy were 40%. Volunteers were
recruited from 13 villages in the North Bank Division of
Gambia in July 2002 with follow-up to December 2002 [26].
The villages were chosen for proximity to the alluvial ﬂood
plain. A strong association between proximity to the ﬂood
plain and entomological inoculation rate has been seen in
this part of Gambia [27], and the entomological inoculation
rate in the study area is likely to have been in the range of 10–
20 infectious bites per year.
Before recruitment, meetings were held with village heads
and elders, followed by general village meetings at which the
study was explained. Volunteers received information sheets
and consent forms translated into the three local languages in
Arabic script, as well as in English. After written informed
consent was obtained by a study physician, age and identity
were checked, pre-test HIV counselling occurred, and
potential volunteers underwent clinical evaluation, including
a full medical history and clinical examination. They were
screened for haematological (full blood count), renal (plasma
creatinine), and hepatic (plasma alanine aminotransferase
[ALT]) dysfunction, and duplicate malaria smears were made.
Exclusion criteria included any chronic illness detected by
clinical evaluation, ALT greater than 42 (international units/
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litre), creatinine greater than 130 (micromoles/litre), packed
cell volume less than 30%, positive antibody ELISA to HIV-1
or HIV-2, simultaneous participation in another clinical trial,
blood transfusion in the month prior to vaccination, previous
experimental malaria vaccination, administration of another
vaccine within 2 wk of vaccination, previous rabies vacci-
nation, allergy to any previous vaccine or to sulphadoxine/
pyrimethamine, history of splenectomy, and any treatment
with immunosuppressive drugs. Eligible volunteers were
given a unique study number and a photographic identity
card. Parental written informed consent was obtained for
volunteers aged 15–17 y.
Procedures
A member of the Data and Safety Monitoring Board
generated and held the randomisation code that associated
each study number with a speciﬁc vaccine. A blocking
procedure was used, and whole villages were enrolled with
sequential study numbers to ensure balanced numbers in
each group. During the course of the study investigators and
volunteers did not know the size of the blocks, nor were they
aware of which vaccine preparation was administered to a
particular volunteer. Opaque sealed envelopes were used for
vaccine allocation. Study numbers were not preprinted on
vials but were written on vials at vaccination. Used vials were
checked for correct allocation off-site. Vaccination was
performed by nurses who played no other part in the trial.
Volunteers were randomly assigned to receive either (1)
two 2-mg doses of DNA ME-TRAP followed by a single 1.53
108-plaque-forming-units dose of MVA ME-TRAP or (2) three
doses of rabies vaccine; injections were given on days 0, 21,
and 42, timed to coincide with the start of the rainy season.
The ﬁrst two doses of vaccine consisted of two intramuscular
injections, one into each deltoid muscle. DNA ME-TRAP was
given as 1 ml and rabies vaccine as 0.5 ml into each arm. The
third dose of vaccine was given as four intradermal injections
into the skin overlying the deltoid muscle, with two injections
into each arm. The malaria vaccine group received MVA ME-
TRAP as four 0.1-ml injections, whereas the control group
received four 0.05-ml injections of rabies vaccine. Two weeks
before administration of the third dose, all volunteers
received three tablets of sulphadoxine/pyrimethamine to
clear blood-stage P. falciparum infections [23].
After each vaccination volunteers were observed for 1 h
and visited at home on the ﬁrst, second, and seventh day
postvaccination for assessment of local adverse events
(discolouration, induration, blister formation, pain, or
limitation of arm motion), systemic adverse events (headache,
nausea, malaise, or elevated axillary temperature), and
unsolicited adverse events. One week and 13 wk after the
third vaccination, venous blood was collected for repeated
measurement of full blood count, ALT, and creatinine.
Since vaccination with MVA causes a characteristic local
reactogenicity in some subjects, speciﬁc steps were taken to
ensure that the participants were evaluated in a double-
blinded manner. Field workers who assessed reactogenicity
after the third dose were different from those who undertook
surveillance during the parasitological follow-up period.
During the surveillance period, starting 2 wk after the third
dose of vaccine, volunteers were visited twice weekly and
asked whether they had attended a health centre. At weekly
visits blood smears and axillary temperatures were taken. At
midweek visits, blood smears and temperature were taken if
symptoms compatible with malaria were present. Investiga-
tors and ﬁeld supervisors made random visits to ensure
accurate data collection. This active case detection was
supplemented by passive case detection by study nurses to
whom volunteers had 24-h access at three of the study villages
and by a clinic at Medical Research Council Farafenni (20 km
from the study villages). Symptomatic malaria was deﬁned as
the presence of asexual P. falciparum parasites at any
parasitaemia with either an axillary temperature of 37.5 8C
or more or one or more of the following symptoms: headache,
myalgia, arthralgia, malaise, nausea, dizziness, or abdominal
pain.
When blood smears were obtained, two sets of duplicate
blood smears (four smears in total) were made. A Field’s stain
was performed on ﬁlms obtained from subjects with possible
clinical malaria and the ﬁlms read immediately. Two further
smears (‘‘A’’ and ‘‘B’’ slides) were stained with Giemsa after
overnight drying; 100 high-power ﬁelds were read by two
slide readers before a ﬁlm was declared negative. The
presence of P. falciparum parasites was conﬁrmed by a
supervisor before a slide was declared positive. The arith-
metic mean of the A and B slides was used to determine
parasite density. If parasite densities for A and B slides were
markedly discrepant, a third read was performed by the
supervisor and this read was used for analysis. Parasite
density was expressed per microlitre (assuming one parasite
per high power ﬁeld equals 500 parasites/ll). Full blood
counts were performed and packed cell volumes were
measured in a CA620 cell analyser (Medonic, Stockholm,
Sweden). ALT (international units/litre) and creatinine
(micromoles/litre) were measured in a Visual analyser (bio-
Me´rieux, Craponne, France).
Effector T cell responses were assessed in ex vivo c-
interferon enzyme-linked immunospot (ELISPOT) assays for
98 volunteers randomly selected from a substudy list
containing a 3:1 ratio of participants receiving malaria
vaccines to participants receiving rabies (control) vaccines.
For this assay, 4 3 105 peripheral blood mononuclear cells
(PBMCs) were assayed as described [28], using Millipore
(Billerica, Massachusetts, United States) MAIP S45 plates for
18–20 h before being developed. Mabtech (Stockholm,
Sweden) antibodies were used, and counting of spots was
performed blinded to vaccine allocation with the Auto-
Immun Diagnostika (Strassberg, Germany) computerised
system. All peptides were at 25 lg/ml concentration. A single
pool contained all ME peptides. Four pools each were used of
20-mer peptides, overlapping by ten amino acids, to span the
entire TRAP antigen of the T9/96 and 3D7 strains of P.
falciparum.
Statistical Analysis
An analysis plan, written before unblinding, speciﬁed
exclusion criteria, statistical methods, and important covar-
iates (age, village of residence, and bednet use [deﬁned as
sleeping nightly under an intact or impregnated bednet]).
Ethnic group, though not speciﬁed as a covariate in the
analysis plan, was found on analysis to be associated with the
risk of infection, and was included as a covariate. The primary
endpoint was time to ﬁrst infection with asexual P. falciparum,
deﬁned as the number of days from the start of the
surveillance period to the date of the ﬁrst positive slide.
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Vaccine efﬁcacy was calculated from the hazard ratio
estimated by Cox’s regression, adjusting for the effects of
prognostic variables. Volunteers who received fewer than
three doses or who were parasitaemic both prevaccination
and at the beginning of surveillance without an intervening
negative blood smear were excluded from the primary
analysis but included in a secondary analysis. Observations
on individuals who were lost to follow-up or were missing
from trial data for 3 wk were censored. Analyses were done
with Stata version 7 (Stata Corporation, College Station,
Texas, United States). ELISPOT responses were analysed as
follows. After subtraction of medium-alone values from each
pooled peptide response, responses were summed across T9/
96 and 3D7 pools. Geometric means were calculated for T9/96
TRAP, 3D7 TRAP, and ME string responses. Responses in the
two groups were compared using the Mann-Whitney test.
Results
In total, 489 volunteers were screened (Figure 1), of whom
117 were excluded for the following reasons: 46 could not be
found on the day of vaccination, 44 were not eligible
(anaemia, ALT, creatinine, HIV, various medical conditions,
too young or too old), and 27 withdrew consent. Thus, 372
volunteers aged 15–45 y were enrolled. Of these, 335 men
(90%) received their second dose of vaccine, and 320 of these
received the third dose. Some 52 volunteers who were
randomised did not receive three doses (two men received
the wrong vaccine at the second dose, 26 left the study area,
23 withdrew consent, and one was withdrawn because he
developed pneumonia between the ﬁrst and second doses). In
total, 296 volunteers (141 in the malaria group and 155 in the
rabies group) received three doses and were followed up, 277
of whom completed 11 wk of surveillance. Additional data
were available for 14 volunteers who did not receive all three
vaccine doses (all 14 received the ﬁrst and third doses), for
two volunteers in the malaria vaccine group who received the
wrong vaccine at the second dose, and for 18 volunteers who
were parasitaemic both before vaccination and at the start of
surveillance. These individuals were included in a secondary
analysis. Losses to follow-up were similar in the two groups.
Prognostic variables were similarly distributed in the two
groups at the start of surveillance (Table 1). This trial is
reported in accordance with CONSORT guidelines (Table
S1).
Vaccine Safety
No clinically signiﬁcant differences in packed cell volume,
ALT, or creatinine were seen in either vaccine group. One
volunteer who received rabies vaccine had a history of
breathlessness and chest pain several years prior to enrol-
ment, experienced a relapse of symptoms, and deteriorated
and died, probably from heart disease, 3 mo after he received
the last dose of vaccine. This event was regarded as unrelated
Figure 1. Trial Profile
DOI: 10.1371/journal.pmed.0010033.g001
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to vaccination. There were no other serious adverse events.
Adverse events were rare after ﬁrst and second doses and
were not increased in the DNA ME-TRAP group compared to
the rabies vaccine group (data not shown). Injection site pain,
limited arm motion, headache, and malaise in the ﬁrst 24 h
after vaccination (mild to moderate in intensity, i.e., not
preventing activities of daily living, in all but one volunteer)
were more common after MVA ME-TRAP vaccination than
rabies vaccination (Table 2). Some volunteers developed an
injection site blister 1–2 d after MVA ME-TRAP vaccination,
which healed over 1–3 wk without complications. Induration
(for 1–2 d) and discolouration (faint, shiny macular appear-
ance for several weeks) were common after MVA ME-TRAP
vaccination. The frequency of short duration severe adverse
events (i.e., preventing activities of daily living) of less than
2% seen with MVA ME-TRAP immunisations is less than that
seen with some other licensed alum-formulated vaccines in
widespread use.
Immunogenicity
In the study, 63 and 30 volunteers from the malaria and
rabies vaccine groups, respectively, were assayed 7 d after
ﬁnal vaccination for T cell responses. In the rabies vaccine
group, geometric mean effector T cell responses were 3.1, 3.9,
and 1.4 spot-forming cells (SFCs) per million PBMCs for T9/
96 and 3D7 strains of TRAP and the ME string, respectively.
In the malaria vaccine group, the effector T cell frequency to
the vaccine strain of the TRAP antigen, T9/96, was geometric
mean 251.1 SFCs per million PBMCs (80-fold increase above
control group, p ,0.001, range 6.25–2148.75). A large cross-
reactive T cell response to 3D7 TRAP, a strain with 6% amino
acid variance to T9/96, and a weaker response to the ME
string were also seen at this timepoint (Table 3).
Time to First P. falciparum Infection
By the end of the study, 171 participants developed
parasitaemia, 80/141 (57%) in the malaria vaccine group
and 91/155 (59%) in the rabies vaccine group. The distribu-
tion of time to ﬁrst infection was similar in the two groups
(Figure 2). Vaccine efﬁcacy among participants who received
three doses, adjusted for age, bednet use, ethnic group, and
village of residence was 10.3% (95% CI,22% toþ34%; p =
0.49). Similar results were obtained when all participants who
received at least one dose of vaccine were included in the
analysis (efﬁcacy, 1.0%; 95% CI, 32% to þ25%; p = 0.95).
Geometric mean P. falciparum densities in ﬁrst infections
were similar in the two groups (31 parasites/ll [IQR, 5–154] in
Table 1. Characteristics of the Trial Cohorts at the Start of Surveillance
Malaria Vaccine (n = 141) Rabies Vaccine (n = 155)
Median age (years [IQR]) 20 (17–32) 21 (18–30)
Village group 1 (Alkali Kunda, Chamen, Yallal) 26 (18%) 29 (19%)
Village group 2a 79 (56%) 93 (60%)
Village group 3 (Bambali) 36 (26%) 33 (21%)
Ethnic group Fula 12 (9%) 19 (12%)
Ethnic group Mandinka 81 (57%) 82 (53%)
Ethnic group Wollof 48 (34%) 54 (35%)
Sleeps nightly under intact or impregnated bednet 76 (54%) 83 (54%)
Table shows the 296 participants who received three doses of vaccine and were followed up.
a Village group 2 consisted of nine closely situated villages.
DOI: 10.1371/journal.pmed.0010033.t001
Table 2. Frequency of Solicited Symptoms during the 7 d after the Third Dose of Vaccine
Category Symptom MVA ME-TRAP Rabies
n Percent 95% CI n Percent 95% CI
Local symptoms Limited arm motion 28/152 18% 13–26 2/158 1.3% 0.2–4.5
Pain 103/152 68% 60–75 19/157 12% 7.4–18
Discolouration 116/151 77% 69–83 26/156 17% 11–23
Induration 138/152 91% 85–94 86/158 54% 46–62
Blister 89/151 59% 51–67 14/156 9.0% 5.0–15
General symptoms Headache 45/161 28% 21–36 19/168 11% 6.9–17
Objective fever 6/161 3.7% 1.4–7.9 0/168 0% 0–2.0
Malaise 40/161 25% 18–32 14/168 8.3% 4.6–14
Nausea 3/161 1.9% 0.4–5.3 1/168 0.6% 0–3.3
Table shows the number and percentage of participants who had at least one report of the symptom.
DOI: 10.1371/journal.pmed.0010033.t002
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the malaria vaccine group compared to 24 parasites/ll [IQR,
5–69] in the rabies group; Mann-Whitney test, p = 0.79).
During surveillance, there were ten episodes of symptom-
atic malaria in the malaria vaccine group and 13 in the rabies
group. The risk of malaria-related symptoms during an
episode of parasitaemia was similar in both vaccine groups.
Percentage mean packed cell volume at the end of the trial
was similar in both groups (41 [IQR, 37–44] for the malaria
vaccine group and 40 [IQR, 37–43] for the rabies group).
Within the ELISPOT substudy group, the risk of developing
parasitaemia was not associated with effector T cell response
to the 3D7 strain of TRAP. The 80 men from the substudy
group who received three doses of either malaria vaccine (55
men) or rabies vaccine (25 men), completed 11 wk of
surveillance, and had complete ELISPOT data after dose
three were divided into four quartiles. Men with the highest
effector T cell responses had hazard ratios for infection
similar to those with the lowest after adjustment for age,
bednet use, and village of residence.
The incidence of parasitaemia decreased with increasing
age, and was decreased in those of Fula ethnicity compared to
those in the Mandinka and Wollof ethnic groups (Table 4).
The use of bednets was not associated with a signiﬁcantly
reduced risk of malaria infection (Table 4).
Discussion
This trial demonstrated that vaccination with two doses of
DNA ME-TRAP followed by a single dose of MVA ME-TRAP
is safe and highly immunogenic for effector T cell induction
but that it did not reduce the P. falciparum infection rate in a
semi-immune adult African population. This provides a
second comparison between protection in malaria-naı¨ve
and malaria-experienced adults. RTS,S/AS02, a circumspor-
ozoite protein malaria vaccine based on a hepatitis B surface
antigen virus-like particle formulated in a proprietary
adjuvant, provided about 40% sterile protection in the
artiﬁcial challenge model [29] and 71% short-term protection
against natural infection [30]. The lack of ﬁeld efﬁcacy found
in the present study despite evidence of partial protection in
United Kingdom volunteers supports the use of complete, not
partial, protection in the sporozoite challenge model as a
predictor of likely ﬁeld efﬁcacy against malaria infection
when screening pre-erythrocytic vaccine candidates. How-
ever, some vaccines are known to prevent disease but not
infection, as is also the case for naturally acquired immunity
to malaria. There was no effect of bednet use on parasitaemia
in either this study or an earlier malaria vaccine trial in adults
[30], whereas bednet use has been found to substantially
reduce the incidence of clinical malaria and childhood
mortality in Gambian children [31]. The present study does
not exclude the possibility that the vaccination regimen
tested could provide signiﬁcant anti-disease immunity.
Paediatric study designs are necessary to evaluate this
possibility. The present study highlights an issue related to
use of surrogate efﬁcacy endpoints; whereas positive results
can spur development, negative results may incorrectly lead
to the cessation of development of a candidate vaccine.
Another possible reason for the observed low efﬁcacy is
that the frequency of the effector T cell response declines
from 7 d after boost, and so efﬁcacy would be prevented if
very high frequencies of circulating effectors are needed for
protective efﬁcacy. Alternatively, a suboptimal regional
memory T cell pool in the liver may be responsible [32], or,
less likely in view of the observed T cell strain cross-reactivity,
TRAP polymorphisms may have impaired T cell recognition.
In previous studies in East and West Africa, summed T cell
responses to TRAP in unvaccinated semi-immune adults by
ex vivo c-interferon ELISPOT were geometric mean less than
20 SFCs per million PBMCs. The candidate regimen
Table 3. Effector T Cell Responses 1 wk after the Third Vaccination
Stimulant Geometric Mean SFCs per Million PBMCs p Value
Malaria vaccine (n = 55) Rabies vaccine (n = 25)
ME peptides 4.70 1.39 0.10
3D7 TRAP peptides 198 3.91 ,0.001
T9/96 TRAP peptides 251 3.30 ,0.001
Of the 98 individuals identified for testing T cell responses, 80 received three doses of vaccine according to protocol and gave analysable responses.
DOI: 10.1371/journal.pmed.0010033.t003
Figure 2. Kaplan-Meier Survival Curves Showing the Probability of
Remaining Free of P. falciparum Infection during the 11 wk of
Surveillance
Week 0 of surveillance began in October 2002, 14 d after the third
dose of vaccine was administered.
DOI: 10.1371/journal.pmed.0010033.g002
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represents a new method for induction of unprecedented
effector T cell frequencies, which are about 50-fold higher
than those induced by lifelong natural exposure. Estimates of
the reduction in liver-stage parasite burden induced by these
vaccines in the human challenge model are of the order of
80%–90% of infected hepatocytes [21,33]. It is unclear
whether a similar level of anti-parasite activity could have
been achieved in this study without any signiﬁcant change in
infection rate. Another candidate malaria vaccine that
reduced liver parasite burden by an estimated 95% in
challenge studies [29,33] did have a substantial, if short-lived,
impact on infection rates in a similar Gambian ﬁeld study
[30]. This suggests that a moderate increase in the efﬁcacy of
this ﬁrst-generation prime-boost vaccination strategy in
reducing liver parasite burden might have an important
impact on overall efﬁcacy.
Second-generation prime-boost vaccine strategies for
malaria currently in or near to clinical evaluation include
the following: use of a different viral vector as the priming
agent that may lead to proportionately greater CD8þ rather
than CD4þ T cell induction (J. M. Vuola, S. Keating, D. P.
Webster, T. Berthoud, S. Dunachie, et al., unpublished data),
as is the case with fowlpox-MVA immunisation; the use of a
different antigen, the circumsporozoite protein, or polypro-
tein constructs [34] to address the difﬁcult issue of target
antigen selection; and evaluation of regimes that seek to
combine high-level T cell responses with strong anti-
sporozoite antibody induction, e.g., protein/adjuvant and
recombinant virus prime-boost immunisation. In the medium
term, combination with protective blood-stage antigens is
also desirable. Determining methods for the successful
combination of different candidate vaccine regimens
(whether within or between parasite stages) will be one of
the important challenges of coming years.
We were unable to obtain a useful estimate of the likely
efﬁcacy of the DNA ME-TRAP/MVA ME-TRAP vaccination
regime against clinical disease. Even for an adult population,
the incidence of clinical disease was lower than expected.
Sulphadoxine/pyrimethamine was administered 4 wk before
the start of surveillance in this study and in an RTS,S ﬁeld
efﬁcacy study [30]. There is some evidence that pretreatment
with this antimalarial reduces the incidence of clinical
malaria for longer than 4 wk [35,36]. However, there was also
less clinical disease than in recent years in paediatric cohorts
recruited for other studies in 2002 at the study site, probably
for climatic reasons.
This study highlights North Bank Division in Gambia as an
excellent malaria vaccine ﬁeld trial site both for adults and,
by extrapolation, for children. In a low-transmission year,
cumulative incidence overall in men aged 15–45 y was 72%
over 11 wk, which was higher than expected. Also, compliance
was good despite a demanding study design, and migration
from the study area was acceptably low.
This paper adds to the body of data detailing the very
gradual acquisition of anti-infection immunity in adults
resident in sub-Saharan Africa [30]. While substantial
immunity to severe malaria is acquired after only a few
infections and anti-disease immunity is acquired in child-
hood, we saw statistically signiﬁcant decreases in incidence of
infection with increasing age in the 15–45 age range (Table 4).
The protection against infection for those with Fula ethnicity
observed in this trial is consistent with a report from Burkina
Faso [37]. The Fulani mostly reside in distinct villages in this
part of Gambia.
Immunological analysis of the high level of protection
inducible by immunisation of humans and animals with
irradiated sporozoites has encouraged attempts to generate
protective immunity by subunit vaccines that induce strong
cellular immune responses. To date the induction of high-
level protective T cell responses against malaria and some
other infectious pathogens has generally required two-
component prime-boost vaccination approaches [38]. We
report the ﬁrst ﬁeld efﬁcacy trial of a subunit vaccine
designed to induce protective immunity through effector T
Table 4. Results of Cox Proportional Hazards Regression Analysis for the Risk of Developing Parasitaemia after Three Doses of Vaccine
Variable Category Number Developing
Parasitaemia
(Total [Percent])
Crude Hazard Ratio
(95% CI)
Adjusted Hazard Ratio
(95% CI)
Vaccine group Malaria vaccine 80/141 (57%) 1 1
Control 91/155 (59%) 1.07 (0.79–1.45) 1.12 (0.82–1.52)
Village group 1 29/55 (53%) 1 1
2 109/172 (63%) 1.18 (0.78–1.78) 0.92 (0.54–1.55)
3 33/69 (48%) 0.93 (0.56–1.54) 0.94 (0.54–1.66)
Age at enrolment (years) 15–17 48/69 (70%) 1 1
18–20 39/72 (54%) 0.66 (0.43–1.01) 0.56 (0.36–0.87)
21–29 41/71 (58%) 0.74 (0.49–1.13) 0.61 (0.39–0.95)
30–45 43/84 (51%) 0.56 (0.37–0.85) 0.46 (0.29–0.73)
Bednet use Yes 89/159 (56%) 0.93 (0.69–1.26) 1.07 (0.75–1.53)
No 82/137 (60%) 1 1
Ethnic group Fula 15/31 (48%) 1 1
Mandinka 86/163 (53%) 1.20 (0.69–2.07) 1.16 (0.65–2.1)
Wollof 70/102 (69%) 1.60 (0.91–2.79) 1.92 (1.02–3.60)
DOI: 10.1371/journal.pmed.0010033.t004
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cell rather than antibody induction. Effector T cell induction
50-fold greater than that generated by natural malaria
infection is now possible through DNA-based heterologous
prime-boost vaccination of humans. However, further devel-
opment of T cell–inducing vaccines will be required to
evaluate the effects of altering the characteristics, target
antigen speciﬁcities, and durability of the induced T cells in
order to generate higher levels of protective immunity
against malaria.
Supporting Information
Trial Registration. This trial has been submitted for registration in
the International Standard Randomised Controlled Trial Number
(ISRCTN) Register. The ISRCTN is ISRCTN05221133; Web site http://
www.controlled-trials.com/isrctn/trial/1/0/05221133.html.
Table S1. Consort Checklist
Found at DOI: 10.1371/journal.pmed.0010033.st001 (55 KB DOC).
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Patient Summary
Background. Malaria kills 1–2 million people a year, mostly children
under the age of five who live in sub-Saharan Africa. Scientists are trying
to develop cheap, safe, and effective vaccines that could be given to
people living in regions where malaria is very common to prevent them
from developing the disease.
What Did the Researchers Find? The researchers enrolled 372 Gambian
men aged 15–45 years into the study. They injected half the men with
two malaria vaccines, one after the other, and half the men with a rabies
vaccine that does not protect against malaria (this vaccine was given so
that ‘‘control’’ participants would have some benefit from being in the
trial) just before the rainy season, when malaria is especially prevalent.
The scientists took blood smears from the men once a week and
checked to see if they had been infected with the parasite that causes
malaria. They found that the men who had been vaccinated became
infected just as quickly as those who had not. Although the two malaria
vaccines in concert did not work, neither did they cause any serious side
effects. The men given the malaria vaccines did produce an immune
response to the vaccines, though not one that was clinically useful.
What Does This Mean for Patients? It looks as though the combination
of these two vaccines is not effective at preventing infection with
Plasmodium falciparum, the parasite that causes malaria. However, there
are other vaccines in development that have not been tested yet.
Resources on the Web. Gates Malaria Partnership (which co-funded the
study): http://www.lshtm.ac.uk/gmp/
Malaria Vaccine Initiative: http://www.malariavaccine.org/
Medicines for Malaria Venture: http://www.mmv.org/pages/
page_main.htm
Roll Back Malaria Partnership: http://rbm.who.int/partnership
The Wellcome Trust (which co-funded the study): http://www.
wellcome.ac.uk/en/malaria/
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